Similar articles

• Efficacy and safety of oral ibrexafungerp in Chinese patients with vulvovaginal candidiasis: a phase III, randomized, double-blind study.

  Wang X, Wang W, Li J, An R, Chen L, Lin J, Xu D, Qiu J, Song W, Patiman M, Ruan H, Wang G, Xue F, Wang X, Luo X, Ruan Q, Shi L, Zhang C, Hu L, Wang S, Shi H, Wang X, Zhang S, Li Y, Lu J, Wang B, Xu H, Ye H, Zhang B, Zhang C, Qian S, Wu Q, Jia W, Li C, Liao Q. Wang X, et al. Infection. 2024 Oct;52(5):1787-1797. doi: 10.1007/s15010-024-02233-w. Epub 2024 Apr 3. Infection. 2024. PMID: 38568411 Free PMC article. Clinical Trial.
• Oral Ibrexafungerp: an investigational agent for the treatment of vulvovaginal candidiasis.

  Azie N, Angulo D, Dehn B, Sobel JD. Azie N, et al. Expert Opin Investig Drugs. 2020 Sep;29(9):893-900. doi: 10.1080/13543784.2020.1791820. Epub 2020 Aug 19. Expert Opin Investig Drugs. 2020. PMID: 32746636 Review.
• Ibrexafungerp: First Approval.

  Lee A. Lee A. Drugs. 2021 Aug;81(12):1445-1450. doi: 10.1007/s40265-021-01571-5. Drugs. 2021. PMID: 34313977 Review.
• Oteseconazole (Vivjoa) for recurrent vulvovaginal candidiasis.

  [No authors listed] [No authors listed] Med Lett Drugs Ther. 2022 Aug 8;64(1656):124-126. Med Lett Drugs Ther. 2022. PMID: 35921077 No abstract available.
• An evaluation of butoconazole nitrate 2% site release vaginal cream (Gynazole-1) compared to fluconazole 150 mg tablets (Diflucan) in the time to relief of symptoms in patients with vulvovaginal candidiasis.

  Seidman LS, Skokos CK. Seidman LS, et al. Infect Dis Obstet Gynecol. 2005 Dec;13(4):197-206. doi: 10.1080/10647440500240615. Infect Dis Obstet Gynecol. 2005. PMID: 16338779 Free PMC article. Clinical Trial.